Xiao Lin

657 total citations · 1 hit paper
23 papers, 438 citations indexed

About

Xiao Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Xiao Lin has authored 23 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Xiao Lin's work include Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lymphoma Diagnosis and Treatment (4 papers). Xiao Lin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lymphoma Diagnosis and Treatment (4 papers). Xiao Lin collaborates with scholars based in China, United States and Canada. Xiao Lin's co-authors include Jie Wang, Yan Yu, Nong Yang, Shun Lü, Yanping Hu, Kejing Ying, Guosheng Feng, Liang Liang, Zhijie Wang and Jianying Zhou and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and RSC Advances.

In The Last Decade

Xiao Lin

21 papers receiving 430 citations

Hit Papers

Tislelizumab Plus Chemoth... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Jie Wang, Shun Lü et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiao Lin China 9 305 240 66 48 47 23 438
James B. Hayden United States 10 177 0.6× 265 1.1× 104 1.6× 58 1.2× 44 0.9× 30 487
Jian You China 14 257 0.8× 210 0.9× 40 0.6× 95 2.0× 68 1.4× 39 517
Xi Jiao China 13 254 0.8× 146 0.6× 106 1.6× 95 2.0× 23 0.5× 21 437
Tuğba Akın Telli Türkiye 10 201 0.7× 140 0.6× 99 1.5× 24 0.5× 30 0.6× 47 389
Wenxiao Jia China 10 219 0.7× 157 0.7× 42 0.6× 57 1.2× 31 0.7× 25 374
Shota Fujimoto Japan 10 147 0.5× 132 0.6× 67 1.0× 33 0.7× 25 0.5× 27 309
Audrey Simonaggio France 10 445 1.5× 278 1.2× 48 0.7× 82 1.7× 22 0.5× 23 567

Countries citing papers authored by Xiao Lin

Since Specialization
Citations

This map shows the geographic impact of Xiao Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao Lin more than expected).

Fields of papers citing papers by Xiao Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao Lin. The network helps show where Xiao Lin may publish in the future.

Co-authorship network of co-authors of Xiao Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao Lin. A scholar is included among the top collaborators of Xiao Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao Lin. Xiao Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Cheng‐Liang, Xiao Lin, Xinwei He, et al.. (2025). Nomogram for predicting survival in breast cancer with lung metastasis based on SEER data. Translational Cancer Research. 14(2). 808–826.
2.
Chen, Xi, et al.. (2024). Risk Factors for Renal Involvement in Childhood Henoch-Schonlein Purpura (IgA Vasculitis). Journal of College of Physicians And Surgeons Pakistan. 34(10). 1258–1261.
3.
4.
Wang, Danfeng, et al.. (2023). The economic burden and quality of life of patients with psoriasis treated with biologics in China. Journal of Dermatological Treatment. 34(1). 2247106–2247106. 5 indexed citations
5.
Tabernero, Josep, Lin Shen, Elena Elimova, et al.. (2022). HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncology. 18(29). 3255–3266. 45 indexed citations
6.
Guo, Xiang, et al.. (2022). Bayesian Basket Trial Design Accounting for Multiple Cutoffs of an Ambiguous Biomarker. Statistics in Biopharmaceutical Research. 14(3). 342–348. 1 indexed citations
7.
Chen, Xi, et al.. (2022). Influence of RETN, IL‐1, and IL‐6 gene polymorphisms on the risk of acne vulgaris in the Chinese population. Journal of Cosmetic Dermatology. 21(10). 4965–4973. 3 indexed citations
8.
Lin, Xiao, et al.. (2022). Peripheral blood IL‐6 levels in systemic sclerosis patients: Correlation between IL‐6 levels and clinical phenotypes. Journal of Cosmetic Dermatology. 21(11). 6086–6091. 10 indexed citations
9.
10.
Wang, Juan, Shun Lü, Yehuan Sun, et al.. (2021). OA03.04 Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(1). S3–S3. 1 indexed citations
11.
Lin, Xiao, et al.. (2021). MiR-30a sensitized lung cancer against neoadjuvant chemotherapy by depressing autophagy. Japanese Journal of Clinical Oncology. 51(5). 675–684. 13 indexed citations
12.
Wang, Jie, Shun Lü, Xinmin Yu, et al.. (2021). Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer. JAMA Oncology. 7(5). 709–709. 246 indexed citations breakdown →
13.
Huang, He, Li Min Chen, Xiao Lin, et al.. (2020). Prognostic Value of the Modified Systemic Inflammation Score in Patients With Extranodal Natural Killer/T-Cell Lymphoma. Frontiers in Pharmacology. 11. 593392–593392. 13 indexed citations
14.
15.
Wang, Jie, Xinmin Yu, Shun Lü, et al.. (2020). Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).. Journal of Clinical Oncology. 38(15_suppl). 9554–9554. 5 indexed citations
16.
Gong, Xiaoyuan, Yang Huang, Xiao Lin, et al.. (2018). Magnetic-targeting of polyethylenimine-wrapped iron oxide nanoparticle labeled chondrocytes in a rabbit articular cartilage defect model. RSC Advances. 8(14). 7633–7640. 6 indexed citations
17.
Li, Zhenxiang, et al.. (2015). Kit formulation for preparation and biological evaluation of a novel 99m Tc-oxo complex with metronidazole xanthate for imaging tumor hypoxia. Nuclear Medicine and Biology. 43(2). 165–170. 17 indexed citations
18.
Chen, Jiarong, Fuyou Wang, Yi Zhang, et al.. (2012). In Vivo Tracking of Superparamagnetic Iron Oxide Nanoparticle Labeled Chondrocytes in Large Animal Model. Annals of Biomedical Engineering. 40(12). 2568–2578. 29 indexed citations
19.
Lin, Xiao, et al.. (2008). [Role of 18F-FDG PET/CT in diagnosis and staging of nasopharyngeal carcinoma].. PubMed. 27(9). 974–8. 6 indexed citations
20.
Fan, Wei, et al.. (2008). [Diagnostic value of FDG-PET in the detection of bone marrow involvement in patients with diffuse large B-cell lymphoma].. PubMed. 29(12). 832–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James B. Hayden Breakdown of academic impact, for papers by Jian You Breakdown of academic impact, for papers by Xi Jiao Breakdown of academic impact, for papers by Tuğba Akın Telli Breakdown of academic impact, for papers by Wenxiao Jia Breakdown of academic impact, for papers by Shota Fujimoto Breakdown of academic impact, for papers by Audrey Simonaggio
Rankless by CCL
2026